Catch up on the top radiology content of the past week.
|Articles|February 16, 2000
Licensing fees boost Sonus’ Q4 profits
Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into
Advertisement
Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into a $10 million patent cross-licensing agreement with Nycomed last September (SCAN 10/13/99). That agreement helped Sonus year-end results considerably as well; the company reported revenues of $12 million for 1999, compared to $5 million in 1998. Net income for the year was $400,000, compared to a net loss of $11.2 million for 1998. Sonus is currently awaiting FDA clearance for EchoGen, its first ultrasound contrast agent, which the company already sells in Europe.
Advertisement
Related to this article
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Diagnostic Imaging's Weekly Scan: September 27 — October 3
2
The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 1
3
Raising Questions on the Prognostic Value of Fractional Flow Reserve from CCTA
4
Emerging Research Insights and New Advances in Neuroradiology
5